Scholarlink

Introduction <p>The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52&#xa0;weeks of follow-up.</p> Methods <p>Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit.</p> Results <p>A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54&#xa0;weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3&#xa0;µm (from 594.1 ± 206.9&#xa0;µm at baseline to 287.2 ± 89.9&#xa0;µm at final visit; <i>p</i> &lt; 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3&#xa0;µm (from 562.1 ± 107.3 to 271.5 ± 90.7&#xa0;µm; <i>p</i> &lt; 0.001). The mean logMAR BCVA gain was 0.77 (<i>p</i> &lt; 0.001) in naïve and 0.38 (<i>p</i> &lt; 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded.</p> Conclusions <p>Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Fevzi Akkan,
  • Ebru Görgün,
  • Burak Erden,
  • Yavuz Kamil Bardak,
  • Nigar Şerif,
  • Mahmut Öztürk,
  • Erkan Çelik,
  • Selim Bölükbaşı,
  • Şefik Can İpek,
  • Tahsin Uzundede,
  • Gamze Karataş,
  • Murat Karapapak,
  • Ece Özal,
  • Osman Murat Uyar,
  • Doğukan Cömerter,
  • Mehmet Numan Alp,
  • Serhat Ermiş,
  • Anıl Korkmaz,
  • Murat Arıcı,
  • Mehmet Egemen Karataş,
  • Nursal Melda Yenerel,
  • Halil Özgür Artunay,
  • Ecem Önder-Tokuç,
  • Veysel Levent Karabaş,
  • Melih Ünal,
  • Ziya Kapran,
  • Hakan Özdemir,
  • Akın Çakır

摘要

Introduction

The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52 weeks of follow-up.

Methods

Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit.

Results

A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54 weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3 µm (from 594.1 ± 206.9 µm at baseline to 287.2 ± 89.9 µm at final visit; p < 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3 µm (from 562.1 ± 107.3 to 271.5 ± 90.7 µm; p < 0.001). The mean logMAR BCVA gain was 0.77 (p < 0.001) in naïve and 0.38 (p < 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded.

Conclusions

Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.